Suppr超能文献

代谢相关脂肪性肝病各亚型在中年人群中的长期心血管结局存在差异。

Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.

机构信息

Department of Preventive Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

出版信息

Hepatol Int. 2022 Dec;16(6):1308-1317. doi: 10.1007/s12072-022-10407-7. Epub 2022 Sep 7.

Abstract

BACKGROUND AND AIMS

The new metabolic dysfunction-associated fatty liver disease (MAFLD) criteria include the following three distinct subtypes: MAFLD with diabetes mellitus (DM), overweight/obese (OW), or lean/normal weight with metabolic dysfunction. We investigated whether long-term cardiovascular disease outcomes differ across the MAFLD subtypes.

METHODS

From a nationwide health screening database, we included 8,412,730 participants (48.6% males) aged 40-64 years, free of cardiovascular disease history, between 2009 and 2010. Participants were categorized into non-MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. The primary outcome was a composite cardiovascular disease event, including myocardial infarction, ischemic stroke, heart failure, or cardiovascular disease-related death. The presence of advanced liver fibrosis was estimated using a BARD score ≥ 2.

RESULTS

Among the study participants, 3,087,640 (36.7%) had MAFLD, among which 2,424,086 (78.5%), 170,761 (5.5%), and 492,793 (16.0%) had OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Over a median follow-up period of 10.0 years, 169,433 new cardiovascular disease events occurred. With the non-MAFLD group as reference, multivariable-adjusted hazard ratios (95% confidence intervals) for cardiovascular disease events were 1.16 (1.15-1.18), 1.23 (1.20-1.27), and 1.82 (1.80-1.85) in the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively. Participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular disease risk than those with OW-MAFLD, irrespective of metabolic abnormalities or comorbidities. The presence of advanced liver fibrosis was significantly associated with a higher cardiovascular disease risk in each MAFLD subtype.

CONCLUSION

Long-term cardiovascular disease outcomes differed across the MAFLD subtypes. Further studies are required to investigate whether preventive or therapeutic interventions should be optimized according to the MAFLD subtypes.

摘要

背景和目的

新的代谢相关脂肪性肝病(MAFLD)标准包括以下三种不同的亚型:伴有糖尿病(DM)的 MAFLD、超重/肥胖(OW)或代谢功能障碍的消瘦/正常体重的 MAFLD。我们研究了 MAFLD 各亚型的长期心血管疾病结局是否存在差异。

方法

我们从全国性健康筛查数据库中纳入了 8412730 名(48.6%为男性)年龄在 40-64 岁、无心血管疾病史的参与者,这些参与者于 2009 年至 2010 年间入组。参与者被分为非 MAFLD、OW-MAFLD、消瘦-MAFLD 和 DM-MAFLD。使用 BARD 评分≥2 来估计是否存在晚期肝纤维化。

结果

在研究参与者中,3087640 名(36.7%)患有 MAFLD,其中 2424086 名(78.5%)、170761 名(5.5%)和 492793 名(16.0%)患有 OW-MAFLD、消瘦-MAFLD 和 DM-MAFLD。在中位随访 10.0 年期间,有 169433 例新发心血管疾病事件。与非 MAFLD 组相比,多变量校正后的心血管疾病事件风险比(95%置信区间)分别为 1.16(1.15-1.18)、1.23(1.20-1.27)和 1.82(1.80-1.85),OW-MAFLD、消瘦-MAFLD 和 DM-MAFLD 组分别如此。消瘦-MAFLD 或 DM-MAFLD 组的心血管疾病风险高于 OW-MAFLD 组,无论是否存在代谢异常或合并症。晚期肝纤维化的存在与每种 MAFLD 亚型的心血管疾病风险升高显著相关。

结论

MAFLD 各亚型的长期心血管疾病结局存在差异。需要进一步研究以确定是否应根据 MAFLD 亚型优化预防或治疗干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验